The Drug Enforcement Administration has told the public in writing when it can act. The notice of intent published in the Federal Register states that a temporary scheduling order placing 7-hydroxymitragynine above a specified threshold into Schedule I "will not be issued before August 5, 2026," and that the agency intends to issue it as soon as possible after that 30-day window closes.
As of today, 7-OH is not federally scheduled. The notice is not an order. The moment the DEA publishes the order, manufacturing, distributing, selling, and possessing covered 7-OH products becomes subject to the criminal, civil, and administrative provisions of the Controlled Substances Act, and the control lasts two years with a possible one-year extension.
A second notice covering three related compounds, mitragynine pseudoindoxyl, MGM-15 and MGM-16, runs on the same schedule.
Why This Matters
Millions of Americans walk past these products weekly. They sit at gas station counters and smoke shop registers in colorful packaging, sold as tablets, gummies, shots, powders, sublingual strips and nasal sprays, with names like 7-OH and 7 Ohmz.
The people most affected are not recreational experimenters. DEA's own review notes that many users report self-treating chronic pain and anxiety, and that users describe moving from traditional kratom leaf to concentrated 7-OH tablets. For a household where someone is using these products daily, an abrupt supply cutoff is a withdrawal problem, and that is a medical conversation worth having before the order lands rather than after.
What 7-OH Actually Is
This is where consumer confusion is doing real damage, and the distinction is narrower than the marketing suggests.
7-hydroxymitragynine is a minor alkaloid naturally present in the kratom leaf, where it makes up less than two percent of total alkaloid content and typically occurs in trace amounts. It can also be synthesized from mitragynine, the leaf's major alkaloid, in a single chemical step.
The molecule is identical whichever way it arrives. What differs is dose. DEA notes that consumers of raw plant material experience an attenuated effect because of competing alkaloids in the leaf, while isolated or semi-synthetic formulations deliver the alkaloid at full potency. One published survey of 250 products sold between September 2024 and February 2025 found single doses ranging from 1 milligram to 700 milligrams.
What the Threshold Covers
The DEA's threshold, adapted from an HHS definition, captures botanical material containing more than 0.050 percent 7-OH on a dry weight basis, and any synthetic or further-processed article exceeding 0.050 percent or containing more than 1.00 milligram of 7-OH.
The agency states explicitly that the action does not apply to botanical kratom products containing naturally occurring 7-OH below that threshold. Extracts, concentrates, processed edibles, and pressed pills are the target.
What the Federal Data Show
The DEA's toxicology testing program, which analyzes biological samples from fatal and non-fatal overdoses, has identified 7-OH in 85 cases since 2019. Of those, 55 were fatal, and 30 were non-fatal, with a median patient age of 36.
An important limitation belongs here rather than at the end. Those samples frequently contained other substances, including fentanyl, benzodiazepines and ketamine, along with related kratom alkaloids. The DEA's data establish that 7-OH is turning up in overdose casework with increasing frequency between 2020 and 2025. They do not establish that 7-OH alone caused those 55 deaths.
Separately, the FDA Adverse Event Reporting System held 86 cases at the time of DEA's February query, of which 79 were classified as serious and nine involved death. Poison centers logged 165 exposure cases involving 7-OH from January through July of 2025, and among single-substance exposures, 35 percent resulted in serious health problems while 67 percent were treated at a health care facility.
What Officials Say
DEA Administrator Terrance Cole said in the agency's announcement that "today's action targets highly concentrated, synthetic 7-OH products," and that the step gives law enforcement and public health partners tools to address an emerging threat.
HHS Secretary Robert F. Kennedy Jr. said the compounds "are dangerous opioids that fuel addiction and put American lives at risk," and that HHS reviewed the science and recommended the action.
Not everyone agrees. Industry group the 7-HOPE Alliance has argued publicly that 7-OH is lawful under the Food, Drug, and Cosmetic Act and has cited researchers who dispute the overdose and dependence findings. Kratom advocacy organizations have taken the opposite position and pushed for scheduling. Readers should weigh those claims against the fact that no controlled clinical trial has established a safe dose for these concentrated products.
Who Faces the Greatest Risk
The highest-risk group is people using concentrated 7-OH daily for pain or anxiety, particularly anyone also taking opioids, benzodiazepines, alcohol or other central nervous system depressants. Combining them raises the risk of respiratory depression.
A separate risk falls on children. The FDA has warned a company selling 7-OH gummies that the packaging could appeal to kids, and candy-like formulations sit within reach in some households.
Nine states already prohibit 7-OH consumption, and several others cap it as a percentage of total alkaloid content, so legal status already varies considerably by address.
Symptoms and Warning Signs to Watch For
Reported effects in poison center cases include nausea and vomiting, agitation, confusion, loss of consciousness, seizure, sweating, rapid heartbeat, elevated blood pressure, and difficulty breathing.
Slowed or stopped breathing, blue-tinged lips, or unresponsiveness or inability to wake someone is an opioid overdose emergency. A published case report documented cardiopulmonary arrest reversed with naloxone after reported 7-OH use, which means standard overdose response applies.
What You Can Do Now
Anyone using these products regularly should talk with a clinician or an addiction medicine provider before the order takes effect. Physical dependence on an opioid-acting substance is treatable, and one documented case required inpatient buprenorphine stabilization for 7-OH withdrawal.
Do not stop abruptly on your own if you have been using daily. Do not substitute an unregulated online seller in anticipation of a ban. Households where anyone uses opioid-acting substances should keep naloxone on hand, and should store any such product where children cannot reach it.
Cost and Access
Naloxone is available over the counter at pharmacies nationwide, and many state health departments and community organizations distribute it free. Medicaid and most commercial plans cover medication for opioid use disorder, including buprenorphine, and federally qualified health centers offer treatment on a sliding-fee scale. SAMHSA's national helpline provides free, confidential referrals around the clock.
What Happens Next
The DEA may publish the temporary scheduling order in the Federal Register any time on or after August 5. The order takes effect on the date of publication. Temporary scheduling orders are not subject to judicial review, and the notice-and-comment process that applies to permanent scheduling does not apply here. A separate HHS public docket on the threshold closed July 31. MedicalDaily will monitor the Federal Register for publication.
The Bottom Line
The newest verified fact is a date: the DEA cannot issue its Schedule I order before August 5, and intends to move quickly after that. The people most affected are daily users of concentrated extracts, for whom a clinician conversation now is more useful than a stockpile. The central uncertainty is exactly when the order publishes and how enforcement will treat products near the threshold.
Developing Story Timeline
July 6, 2026: Two DEA notices of intent publish in the Federal Register, starting the 30-day clock and setting August 5 as the earliest order date.
July 1, 2026: DEA announces the filings; the notice is signed by Administrator Terrance Cole.
March 6, 2026: HHS advises DEA it has no objection to temporary Schedule I placement above the specified threshold.
February 24, 2026: DEA transmits its required notice to the HHS Assistant Secretary for Health.
